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Abstract
Antithrombin (AT) circulates in plasma in two isoforms,
AT-· (90–95%) and AT-ß (5–10%). AT isoform propor-
tions were measured in plasma samples of 17 healthy
subjects and 26 posttraumatic or postoperative septic
patients, as well as in 4 commercially available AT con-
centrates. Total AT was immune-purified from plasma
and concentrates. Micellar electrokinetic chromatogra-
phy was used to analytically separate and quantify the
isoforms. Compared with plasma samples of healthy
donors, septic plasmas revealed significantly reduced
AT activity (p ! 0.001) and ß-isoform content (p ! 0.05).
AT-ß correlated inversely with urea and creatinine serum
concentrations (p ! 0.01), indicating a relationship be-
tween better renal function and higher ß-isoform con-
tent. ß-Isoform neither correlated with age, gender, and
28-day mortality, nor with plasma concentrations of var-
ious inflammatory and organ function parameters. The
commercial AT concentrate, which is equivalent to the
current WHO standard, had an AT-ß content close to that
found in plasma of healthy subjects. The availability of
this novel quantitative AT isoform assay allows, for the
first time, a closer look at the role of AT isoforms in
hemostasis and sepsis pathophysiology.
Copyright © 2002 S. Karger AG, Basel
Introduction
Antithrombin (AT) is one of the most important pro-
tease inhibitors in plasma-regulating blood coagulation
[1, 2]. In healthy subjects, AT circulates in two isoforms,
AT-· (90–95%) and AT-ß (5–10%). AT-ß, lacking a car-
bohydrate chain close to the heparin binding site, has a
higher affinity to heparin and other glycosaminoglycans
[3–6]. As glycosaminoglycans (GAGs) accelerate the in-
teraction of AT with its target proteases like thrombin and
factor Xa, it is assumed that the ß-isoform constitutes the
more important part of AT, acting as first ‘shield of
defense’ against proteolytic imbalance [7, 8]. Further-
more, GAGs serve as cell surface- and matrix-binding
partners for AT. In vitro and in vivo studies showed the
ß-isoform to be primarily colocalized with GAGs [7, 9,
10]. In the absence of GAGs, the ß-isoform appears to be a
better inhibitor of factor IXa and factor Xa than AT-·
[11, 12].
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In clinical states like disseminated intravascular coagu-
lation (DIC), trauma, shock and sepsis, all associated with
massive injury of the vessel wall, rapid AT consumption
is observed [13–16]. As decreased AT plasma levels corre-
late with increased mortality, the concept of exogenous
AT substitution has been established [17–21]. Due to the
lack of suitable quantification methods, neither sound
data on potential alterations of plasma AT isoform pat-
terns during septic states, nor information on AT isoform
proportions in different AT concentrates have become
available so far. This paper reports on the suitability of
micellar electrokinetic chromatography to quantify AT
isoforms in complex protein solutions, in particular after
immune adsorption of total AT. We also looked for poten-
tial therapeutic and pathophysiological roles for AT iso-
forms, as AT-ß isoform content is correlated with clinical-
ly important parameters of organ function and plasma
parameters of septic inflammatory response.
Material and Methods
Cyclodextrin-Modified Micellar Electrokinetic Chromatography
Cyclodextrin-modified micellar electrokinetic chromatography
(CD-MEKC) was used to analytically separate AT-· and -ß. Separa-
tion in capillary zone electrophoresis is based on the differences in
electrophoretic mobility, resulting in different migration velocities of
ionic species in the electrophoretic buffer contained in the capillary.
MEKC is a high-resolution technique providing an additional selec-
tivity mechanism [22–24]. It is based on micellar solubilization and
electrophoretic migration of the micelle, i.e., the solutes are separated
by the differential distribution between the micelle and the surround-
ing aqueous phase, as well as the differential migration of the two
phases. By using surfactant micelles, a charged vehicle is provided to
perform an electrophoretic separation of both neutral and charged
solutes. The separation process of the solutes between micelles can be
influenced by chiral selectors like cyclodextrins [25]. A 270A-HT
Capillary Electrophoresis System (Applied Biosystems, USA),
equipped with a monochromatic UV detector and a polyimide-
coated fused silica capillary (50 cm effective length, 50 Ìm i.d. ! 363
Ìm o.d., Supelco, USA) was used. Separations were run in 0.06 M
boric acid, 0.04 M sodium dodecylsulphate, 0.02 M ß-cyclodextrin,
0.001 M diaminopentane, at a pH of 9. Solutions (0.5–5 nl) contain-
ing 0.1–1.0 mg/ml AT were applied. Quantification of isoforms was
performed by peak area integration. The technique has recently been
described in more detail [26].
AT Isoform Determination in Complex Protein Solutions
Separation of AT Isoforms and Validation of MEKC Analysis. AT
III isoforms were prepared from AT III concentrate (Kybernin®P,
Aventis Behring GmbH, Germany) by adsorption to Heparin-Frac-
togel®. Twenty thousand units of AT III were dissolved in 2.0 liters of
water for injection (WFI) and pumped onto the heparin column (500
ml), which had been equilibrated with 0.015 M Na2H(PO4)-2-
hydrate, 0.06 M NaH2(PO4)-2-hydrate, 0.05 NaCl, pH 7.2.
The ·-isoform of AT was obtained by increasing the ionic
strength up to 0.8 M NaCl in equilibration buffer, whereas the ß-AT
isoform was eluted with 2 M NaCl. Both preparations were dialyzed
against 0.01 M Na-citrate, 0.15 M NaCl, pH 7.4. Concentrations
were adjusted according to the respective heparin cofactor activity or
AT protein (at 150 Ìg/IU AT). It had been ensured that the described
procedure had no denaturing impact on the preparations. On aver-
age, 97% of the AT solution (activity) applied to the column was
recovered.
Beside the characteristic that the ß-isoform displays a higher
affinity to heparin and therefore elutes at higher ionic strength, it was
analytically identified by SDS-PAGE and isoelectric focusing, as
described by other working groups [4–7, 26]. Both methods, but in
particular the first, provide semi-quantitative methods for the differ-
entiation of both isoforms.
Purified isoforms as well as defined mixtures were used to vali-
date the MEKC conditions, as described below and as recently
reported in more detail [27].
In general, AT activities were quantified using the Berichrom®
AT assay (Dade Behring GmbH, Germany). AT antigen concentra-
tions of flow-through and eluate fractions were determined employ-
ing an ELISA (Kordia BV, The Netherlands).
Purification of AT from AT Concentrates and Human Plasmas
Prior to MEKC analysis, AT was purified from plasma by
immune-adsorption to a monoclonal antibody (mAb-5) bound to
BrCN-Sepharose® (Amersham Pharmacia Biotech AB, Sweden).
mAb-5 directed against AT has been demonstrated to bind both
isoforms with comparable affinity, employing plasmon resonance
technique using a Biacore® system. Association/dissociation con-
stants were calculated according to the equipment provider’s instruc-
tions: for AT-· and AT-ß we found KA values of 1.91 ! 108 M–1
(Kass: 5.46 ! 104 M–1 ! s–1; Kdiss: 2.86 ! 10–4 M–1 ! s–1 ) and 1.87
! 108 M–1 (Kass: 5.52 ! 104 M–1 ! s–1; Kdiss: 2.95 ! 10–4 M–1 !
s–1 ), respectively. This mAb was used for the following experiments.
Solutions (0.5 ml) containing 50 IU/ml of AT-·, AT-ß or different
mixtures thereof in 0.01 M Na-citrate, pH 7.5, were pumped onto
immune-adsorbent columns (10 ml at 1 mg mAb-5/ml of gel each).
After washing the columns with 0.01 M Tris, 1.0 M NaCl, pH 8.0, AT
was eluted with 0.1 M glycine, pH 2.5. The eluates were immediately
adjusted to pH 7.5 by addition of a sufficient volume of 1.0 M Tris,
pH 9.0. Column flow-through fractions, wash solutions and eluates
were tested for AT activity and by MEKC. mAb-5 was identified as
suitable for immune adsorption in terms of recovery of activity and
·-ß content compared with the raw material (table 1). Initial SDS-
PAGE runs and MEKC investigation revealed that AT-· contained
only 0.8% of residual AT-ß, whereas the AT-ß preparation contained
about 3% of the ·-isoform (not shown). These baseline contents were
taken into consideration when calculating the recovery after immu-
noadsorption (i.e. were subtracted from the total content found).
Column overloading experiments had been performed in order to
ensure that the isoform proportions of the samples applied were not
altered by the immune-adsorption procedure. Increasing amounts
(25, 50, 100, 250 IU AT per column) of an AT solution containing
10% AT-ß were applied to the mAb-5 columns. Eluates were ana-
lyzed as described above. When exceeding 25 IU of total AT applied,
the column flow-throughs (FT) contained increasing AT activity, as
expected. The AT-ß content of the eluates (and the FT fractions),
however, did not change significantly and did not decrease with
increasing total amounts applied (eluates: mean 9.6, SD 0.2, range
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Table 1. Evaluation of the immune
adsorption step prior to MEKC Sample AT-ß content
spiked
Recovery in eluate activity
mean SD
AT-ß content measured
mean SD
AT-· 0.8 87.5 3.1 0.8 0.01
AT-ß 97.0 89.0 2.2 97.0 0.5
AT-·/AT-ß 2.0 90.1 2.8 1.9 0.05
AT-·/AT-ß 5.0 88.3 1.1 5.1 0.1
AT-·/AT-ß 10.0 86.4 2.5 10.5 0.2
AT-·/AT-ß 15.0 87.9 3.3 14.2 1.3
AT-·/AT-ß 50.0 92.3 3.0 47.7 2.3
All figures are percentages.
9.3–10.0%). Furthermore, increasing volumes of citrated plasma
samples were immune adsorbed and treated as described above.
Again we found no significant drift in isoform ratios (not shown). We
used AT-deficient plasma (DP, in-house) as control, which revealed a
residual AT activity of !0.5% (compared with the reference plasma);
AT-ß was not detectable in the DP. Spiking experiments of purified
isoform mixtures in the DP revealed recoveries of 190% of activity
and 195% of the AT-ß content expected.
AT concentrates from Aventis Behring, Grifols (Germany), Bax-
ter (Germany) and Pharmacia Upjohn (Germany) were investigated,
three of which revealed high purity. As we observed a peak overlap of
another plasma protein with that of the ß-isoform upon MEKC of the
less pure concentrate C, prior immune adsorption became necessary.
As a consequence, all concentrates were processed equivalently. AT
from standard human plasma (SHP), representing a pool of more
than 100 healthy donors, was purified accordingly.
Three milliliters of mAb-Sepharose (5 mg mAb-5/ml gel) were
used to prepare AT from 1 to 3 ml of the respective citrated plasma
sample, which had been diluted 10-fold in 0.15 M saline beforehand.
After washing of the mAb resin with 25 column volumes each of 0.01
M Tris/HCl containing 2 M NaCl, pH 8.5, and water, AT was eluted
with a solution of 0.1 M glycine, at a pH of 2.5. The eluates were
adjusted to pH 7.0–7.4 immediately and were concentrated by ultra-
filtration (5 kD filter, Millipore, USA) to 0.1–1.0 mg/ml of total pro-
tein. In parallel, the buffer was exchanged to 0.01 M sodium-citrate,
0.15 M NaCl, pH 7.4, and the AT solutions were subjected to MEKC
thereafter.
Blood Sampling and Quantification of Organ Dysfunction and
Inflammatory Response
Citrated blood and serum were drawn from 17 healthy donors (10
male, 7 female; mean age: 43.2 B 11.8 years) and from posttraumatic
and postoperative patients (18 male, 8 female; mean age: 61.3 B 13.8
years) on admission to the surgical intensive care unit of the Munich
University Hospital Grosshadern due to severe sepsis, as defined by
the consensus criteria [17]. Underlying diseases were malignancies
(16), obstructive pulmonary disease (3) and polytrauma (7). Severity
of organ dysfunction was assessed by the measurement of hematolog-
ical and clinical chemistry tests, as well as by blood gas analysis. Pul-
monary gas exchange was expressed as the PaO2/FiO2 ratio, as has
been described previously [17]. This ratio is an appropriate measure
of pulmonary function at different levels of inspired oxygen concen-
tration and positive end-expiratory pressure ventilation [17]. To
quantify liver dysfunction, we determined serum concentrations of
bilirubin [17]. Kidney function was estimated by the determination
of urea and creatinine concentrations by routine laboratory proce-
dures (normal urea values: !50 mg/dl; creatinine: !1.0 mg/dl). No
patient had continuous renal replacement therapy or chronic renal
failure.
Ten out of the 26 patients suffered from DIC, which was defined
by fulfilling 3 out of the 4 the following criteria: concentration of
serum fibrinogen !1.5 g/l; platelet count !150 G/l; partial thrombo-
plastin time: 145 s; prothrombin time: !60% of normal [17].
In order to quantify the inflammatory response and investigate
potential relationships with AT-ß content, interleukin-6 (IL-6), inter-
leukin 8 (IL-8), circulating intercellular adhesion molecule-1 (ICAM-
1), E-selectin, and PMN elastase were determined by using commer-
cially available ELISA kits according to the manufacturers’ instruc-
tions (IL-6: R & D Systems, USA; IL-8: Amersham, Germany; solu-
ble ICAM-1 and E-selectin: Serva/Bender, Germany; PMN elastase:
Merck, Germany). Normal values given by the manufacturers are:
IL-6: 0–6 pg/ml; IL-8: 0–30 pg/ml; ICAM-1: 180–280 ng/ml; E-
selectin: 15–25 ng/ml; PMN elastase: 80–120 ng/ml.
Statistics
Data are presented as mean values and standard deviations (SD).
AT activity and ß-isoform content between 2 groups were compared
by the unpaired Student’s t test or the unpaired Wilcoxon rank test
where appropriate. A one-way analysis of variance with appropriate
post hoc tests was used to compare AT activity and isoforms in more
than 2 groups. Spearman correlation coefficients (two-tailed signifi-
cances) were calculated by the SPSS software package (SPSS, version
10.0, Chicago, USA). A significance level of p ! 0.05 was chosen to
indicate statistical significance.
Results
Quantification of AT-ß Isoform Levels by CD-MEKC
Using CD-MEKC under the conditions described, a
sufficient separation of the isoforms was achieved in
order to quantify AT-· and -ß. Although an estimation of
total AT concentrations is possible with this method, we
were mainly interested in the proportion of the isoforms,
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Fig. 1.  Electropherograms of AT isoform
separations by CD-MEKC
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No. PET Height Area Area %
a Purified AT-· (30%) and -ß (70%) mixture
1 14.571 9.018 51.631 29.520
2 14.999 23.973 123.273 70.480
b AT concentrate
1 14.435 26.261 195.948 96.594
2 14.842 1.014 6.909 3.406
PET = Peak elution time.
which was expressed as percent AT-ß content of total AT
(·- plus ß-isoforms). Spiking experiments showed that a
quantification covering a broad proportion range was pos-
sible. Exemplary separation electropherograms of a
mixture of the purified isoforms (30% ·- and 70% ß-
isoform) and of a high purity AT concentrate are shown
(fig. 1a, b).
AT Activity and ß-Isoform Content of Plasma Samples
and Standard Human Plasma
The evaluation of 17 plasma samples of healthy sub-
jects revealed a mean AT activity of 0.99 IU/ml (SD: 0.08
IU/ml), ranging from 0.87 to 1.12 IU/ml. Pool plasma
(SHP; 1100 donations) had an activity of 1.0 IU/ml by
definition. Septic plasmas (n = 26) displayed a significant-
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ly (p ! 0.0001) reduced AT activity, with a mean level of
0.65 IU/ml (SD: 0.2 IU/ml), ranging from 0.3 to 1.1 IU/
ml.
AT of each plasma sample was obtained by separate
immune adsorption prior to MEKC. In pre-experiments,
the eluates were investigated on AT activity in relation to
AT protein (as determined by ELISA). Compared to the
individual plasma samples, more than 95% of AT-specific
activities were recovered after immune-adsorption, indi-
cating that this procedure did not significantly harm AT.
Standard human plasma contained 7.4% AT-ß. On
average, plasma of healthy donors had a 7.8% ß-isoform
content (B 1.4% SD), ranging from 5.9 to 10.7%, whereas
plasma from septic patients showed a significantly re-
duced mean 6.6% AT-ß content B 2.0% SD), ranging
from 3.0 to 10.5% when compared to healthy donors’
plasma pool (p = 0.027). There was no correlation be-
tween AT activity and ß-isoform content in the plasma
samples from healthy donors and from sepsis patients
(fig. 2).
When comparing sepsis patients without DIC with
those suffering from DIC, as defined by Inthorn et al. [17],
there were no significant differences in AT activity (non-
DIC: 0.65 B 0.22 IU/ml SD, vs. DIC: 0.65 B 0.18 IU/ml
SD) and AT-ß levels (non-DIC: 7.1 B 1.8% SD, vs. DIC:
6.5 B 2.0% SD).
Correlation of AT-ß Isoform Content with Gender,
Age, Clinical Outcome and Organ Function
Parameters
We did not detect any difference between AT-ß con-
tents in female and male healthy volunteers (female: 7.9
B 1.2% SD, male: 7.8 B 1.8% SD) or female and male
septic patients (female: 6.5 B 2.7% SD, male: 5.6 B 1.5%
SD). No correlation was found between ß-isoform content
and age in healthy volunteers and septic patients (r =
–0.22; p = 0.27). AT-ß content did not significantly differ
between patients who survived 28 days and patients who
died within this period (alive at day 28: 6.3 B 1.7% SD;
died before day 28: 5.3 B 2.2% SD), or between patients
who survived and those who died (survivors: 6.6 B 1.9%
SD; non-survivors: 5.7 B 1.9% SD).
We did neither observe a correlation between AT-ß
content and PaO2/FiO2 ratio (r = –0.26, p = 0.27) nor AT-
ß and serum bilirubin (r = 0.06, p = 0.78). However,
inverse correlations of both, AT-ß content and serum
creatinine (r = –0.41, p ! 0.05), as well as AT-ß content
and serum urea (r = –0.65, p ! 0.001) were observed
(fig. 3a, b).
Fig. 2. Correlation of AT activity and AT-ß content in plasma of
healthy (n = 17) and septic patients (n = 26). P = Healthy controls;
g = septic patients.
Correlation of AT-ß Isoform Content and Parameters
of Inflammatory Response in Septic Patients
At the time of sepsis diagnosis, we did not observe a
significant correlation between IL-6 and IL-8 concentra-
tions and AT-ß content (IL-6: r = –0.24, p = 0.41; IL-8: r =
–0.33, p = 0.25). Neither soluble ICAM-1 and E-selectin
concentrations nor elastase contents related with circulat-
ing AT-ß levels (ICAM-1: r = –0.13, p = 0.60; E-selectin:
r = –0.22, p = 0.44; PMN elastase: r = –0.08, p = 0.72).
AT-ß Isoform Content in Different AT Concentrates
Considerable differences in the ß-isoform content of
4 investigated commercially available AT concentrates
were found. Concentrate A (n = 27 lots) had an average
AT-ß content of 5.2%, concentrate B of 1.7% (SD: 1.0%,
range: 0.3–3.1%), C of 3.9% and D of 2.2% (table 2).
While all concentrates showed, on average, lower AT-ß
isoforms than the plasma of healthy donors (p ! 0.01),
concentrate A contained significantly (p ! 0.01) more AT-
ß than the other products. AT-ß in concentrate C was sig-
nificantly (p ! 0.01) higher than in concentrates B and D,
whereas the two latter did not differ significantly (p = 0.3)
from each other.
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Fig. 3. Correlation of AT-ß content with creatinine (a) and urea (b) concentrations in plasma of septic patients (n = 26).
Table 2. AT-ß contents of four AT
concentrates Concentrate AT-ß content
mean value SD range
p value
A, n = 27 5.2 0.7 4.3–6.7 A vs. B, C, D: p ! 0.01
B, n = 12 1.7 1.0 0.3–3.1 B vs. D: p = 0.3 
C, n = 8 3.9 0.7 3.3–5.5 C vs. B, D: p ! 0.01
D, n = 11 2.2 0.9 1.1–3.9
Unless otherwise stated, all figures are percentages.
Discussion
Recently we reported about CD-MEKC allowing the
exact determination of AT isoform proportions in albu-
min-diluted solutions or high-purity AT concentrates
without further processing [26]. This method provides an
advantage over other electrophoretic methods reported
[27]. In complex protein solutions it is, however, neces-
sary to isolate AT by immune adsorption beforehand.
AT isoform proportions in plasma samples of healthy
subjects, septic patients, and AT concentrates were ex-
pressed as percent AT-ß. The measured AT-ß levels in
healthy subjects, ranging from 5.9 to 10.7%, are in line
with the results reported by other working groups, using
gel electrophoresis and scanning of stained protein bands.
Besides, the mean value of 7.8% found in healthy volun-
teers agrees well with 7.4% measured in SHP, which
represents a pool of more than 100 healthy donors.
The biological importance of the AT-ß isoform was
stressed by a recent publication on a family displaying an
Asn135Thr AT mutation, which affects the consensus
sequence responsible for the glycosylation close to the
heparin binding site [28]. As a consequence, plasma of
certain members of this family contains a significantly
increased ß-isoform content. As these subjects have not
been suffering from thrombosis despite an AT activity of
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only 70%, it was assumed that the greater AT-ß content
may have provided a protective effect due to its probably
more efficient anticoagulant properties. Thus, according
to the current hypothesis that the ß-isoform plays the pre-
dominant role in, for instance, thrombotic events, we sup-
posed that AT-ß consumption during DIC might signifi-
cantly affect the isoform proportion in plasma from septic
patients.
Although the difference between healthy and sepsis
plasma ß-isoform content reached statistical significance
(p = 0.027), the broad concentration ranges found in both
groups overlapped to a certain extent. In fact, we did not
find a correlation between AT consumption measured by
decreasing AT activity and ß-isoform content in septic
plasma. Although we recently demonstrated that both AT
isoforms were inactivated to the same extent by PMN
elastase in vitro [12], we cannot exclude that proteolytic
inactivation contributed to the correlation of decreasing
AT activity and ß-isoform contents in this study.
Furthermore, we tried to further elucidate the biologi-
cal AT-ß importance by analyzing its correlation with
well-established parameters of multiple organ dysfunc-
tion and pro-inflammatory response. Interestingly, we
found a significant correlation between higher AT-ß con-
tent and improved kidney function, which was reflected
by lower urea and creatinine plasma concentration. Since
neither organ function parameters like bilirubin and
PaO2/FiO2 ratio and 28-day mortality, nor hospital mor-
tality or inflammatory mediator concentrations corre-
lated with AT-ß content, the biological significance of this
finding remains unclear at present. From our results, it
may be speculated that increased AT-ß consumption in
septic patients reflects a significantly enhanced AT me-
tabolism, which is necessary to counteract multiple me-
diators and proteases released from endothelium and
subendothelium upon diverse stimuli. Furthermore, it
has to be considered that the number of patient samples
analyzed was limited. The results reported have to be con-
firmed by a larger study in the future.
Sepsis and DIC are associated with high mortality. A
recent clinical sepsis study suggested a clinical benefit (90-
day mortality) in a patient subgroup receiving AT without
concomitant heparin [29]. Regarding clinically important
differences between the available AT concentrates, only
few clinical studies showing considerable differences in
the in vivo AT recovery during supplementation have
been published so far [30]. However, purity, which is a
result from different production procedures, also differs
considerably between different AT concentrates [31, 32].
According to our study, significant variations in the ß-
isoform contents of different concentrates are obvious. In
concentrate A, which is equivalent to the current WHO
AT standard, ß-isoform contents were found to be close to
the average plasma levels of healthy donors [33], whereby
concentrate A contained significantly higher amounts of
AT-ß than concentrates B, C and D. In concentrates B and
D we found minimal AT-ß levels – close to 1% or even
below – reflecting differences in the manufacturing pro-
cess, which includes heparin adsorption as the main puri-
fication step. Adsorption and elution conditions influence
the yields of the ß-isoform, as well as different plasma
fractions used as raw material [34–36].
As a consequence, administration of AT concentrates
with low AT-ß content might result in a systemic AT-ß
depletion. However, the biological significance of AT-ß
deficiency during different clinical states remains to be
elucidated.
The availability of the new assay system for determina-
tion of AT isomer content now facilitates a closer look at
the role of AT isoforms and their metabolism during
homeostasis and under pathophysiological conditions.
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